- Home
- STCN vs BOLD Comparison
STCN vs BOLD Comparison
Compare STCN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STCN
- BOLD
- Stock Information
- Founded
- STCN 1986
- BOLD 2018
- Country
- STCN United States
- BOLD United States
- Employees
- STCN N/A
- BOLD N/A
- Industry
- STCN Advertising
- BOLD
- Sector
- STCN Consumer Discretionary
- BOLD
- Exchange
- STCN Nasdaq
- BOLD Nasdaq
- Market Cap
- STCN 63.4M
- BOLD 81.0M
- IPO Year
- STCN 1994
- BOLD 2024
- Fundamental
- Price
- STCN $10.40
- BOLD $2.95
- Analyst Decision
- STCN
- BOLD Strong Buy
- Analyst Count
- STCN 0
- BOLD 3
- Target Price
- STCN N/A
- BOLD $23.00
- AVG Volume (30 Days)
- STCN 11.9K
- BOLD 57.8K
- Earning Date
- STCN 12-12-2024
- BOLD 11-11-2024
- Dividend Yield
- STCN N/A
- BOLD N/A
- EPS Growth
- STCN 203.29
- BOLD N/A
- EPS
- STCN 3.17
- BOLD N/A
- Revenue
- STCN $169,044,000.00
- BOLD N/A
- Revenue This Year
- STCN N/A
- BOLD N/A
- Revenue Next Year
- STCN N/A
- BOLD N/A
- P/E Ratio
- STCN $3.19
- BOLD N/A
- Revenue Growth
- STCN N/A
- BOLD N/A
- 52 Week Low
- STCN $7.36
- BOLD $2.82
- 52 Week High
- STCN $13.00
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- STCN 57.19
- BOLD N/A
- Support Level
- STCN $9.90
- BOLD N/A
- Resistance Level
- STCN $10.29
- BOLD N/A
- Average True Range (ATR)
- STCN 0.39
- BOLD 0.00
- MACD
- STCN 0.11
- BOLD 0.00
- Stochastic Oscillator
- STCN 100.00
- BOLD 0.00
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.